XON9 / Xenothera - LARVOL DELTA

Characterization of XON9, an effective glyco-humanized polyclonal antibody against hepatocarcinoma (AACR 2025) - "Multikinase inhibitors (Sorafenib or Lenvatinib) are the conventional first line treatment for unresectable HCC, with limited response rates and serious side effects. Although recent immunotherapy advances have been made, hepatocarcinoma remains an incurable disease with a real need for innovative therapies. XON9 represents a promising and selective immunotherapy against refractory hepatocarcinoma."

Liver Cancer • Oncology • CASP8 • CASP9

XON9-A Glyco-Humanized Polyclonal Antibody Effective Against Hepatocellular Carcinoma. (PubMed, Int J Mol Sci) - "Treatments for advanced HCC include multikinase inhibitors (Sorafenib or Lenvatinib), with limited response rates and serious side effects, or immunotherapy applicable to a small fraction of patients. No toxicity was observed after repeated injections of XON9 in a non-human primate. XON9 represents a promising and selective immunotherapy against refractory HCC."

Journal • Hepatocellular Cancer • Oncology • Solid Tumor • CASP8 • CASP9